Socioeconomic disparities and the genomic landscape of gastric cancer

• Published in: Scientific reports 2024-07, Vol.14 (1), p.15070-11, Article 15070
• Main Authors: Zanabria, Daniel, Galvez-Nino, Marco, Araujo, Jhajaira M., Alfaro, Alejandro, Fajardo, Williams, Saravia, Luis, Quispe, Lidia, Velazque, Gina, Carbajal, Junior, López, María J., Jimenez, Sergio, Montenegro, Paola, Zevallos, Alejandra, Clavo, Maria de los Angeles, Medina-Pérez, Paula, Cornejo, Melanie, Requena, María, Aguilar, Alfredo, Pinto, Joseph A.
• Format: Article
• Language: English
• Subjects: 631/208/68; 631/208/721; 631/67; 631/67/1059; 631/67/69; Adenocarcinoma; Adenocarcinoma - genetics; Adult; Aged; Cancer; E-cadherin; Female; Gastric cancer; Genomics; Genomics - methods; Humanities and Social Sciences; Humans; Immunotherapy; Male; Middle Aged; multidisciplinary; Mutation; Next-generation sequencing; p53 Protein; Peru - epidemiology; Pilot Projects; Prospective Studies; Risk factors; Science; Science (multidisciplinary); Social Class; Socioeconomic Disparities in Health; Socioeconomic Factors; Socioeconomic status; Socioeconomics; Sox9 protein; Stomach Neoplasms - genetics; Targeted therapy
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-65912-6

The genomic characteristics of Peruvian patients with gastric adenocarcinoma from diverse socioeconomic backgrounds were examined in consideration of the possibility that patients from different socioeconomic backgrounds may be exposed to different risk factors. We conducted a prospective pilot study in two Peruvian cities (Lima and Ica). This study enrolled 15 patients from low socioeconomic status (LSES) and 15 patients from medium/high socioeconomic status (MHSES). The genomic profiling of gastric adenocarcinoma samples was done through the FoundationOne CDx platform. We compared the genomic characteristics and the need for targeted therapy and immunotherapy between LSES and MHSES. The genes with higher rates of alterations were TP53 (73.3% vs. 50.0%, P  = 0.2635); CDH1 (26.7% vs. 28.6%, P  = 1); CDKN2A (20.0% vs. 28.6%, P = 1); KRAS (33.3% vs. 7.1%, P  = 0.1686); ARID1A (20.0% vs. 14.3%, P  = 1); MLL2 (13.3% vs. 21.4%, P  = 1) and SOX9 (33.3% vs. 0.0%, P  = 0.0421) in LSES versus HMSES, respectively. There was no significant difference in tumor mutational burden ( P  = 0.377) or microsatellite status ( P  = 1). The LSES group had a higher need for targeted therapy or immunotherapy according to gene involvement and alterations. A significant genomic difference exists among patients with gastric adenocarcinoma of different socioeconomic status, which may result in a different need for targeted therapy and immunotherapy.